Autologous stem cell transplantation in chronic myeloid leukaemia: A meta-analysis of six randomized trials

Cancer Treatment Reviews

Volumn 33, Issue 1, 2007, Pages 39-47

[No Author Info available]

Author keywords

Autologous stem cell transplantation; Chronic myeloid leukaemia; Randomized meta analysis

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYTARABINE; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; IMATINIB; INTERFERON; MELPHALAN; PROTEIN TYROSINE KINASE INHIBITOR;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOGENETICS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FOLLOW UP; HUMAN; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL MOBILIZATION; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33846417303     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.10.002     Document Type: Review

References (22)

1. Haines M.E., Goldman J.M., Worsley A.M., et al. Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients. Br J Haematol 58 (1984) 711-721
2. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89 (1997) 1616-1620
3. Simonsson B., Oberg G., Killander A., et al. Intensive treatment in order to minimise the Ph positive clone in chronic myelogeneic leukaemia (CML). Bone Marrow Transplant 14 Suppl. 3 (1994) S55-S56
4. Carella A.M., Podesta M., Frassoni F., et al. Collection of "normal" blood repopulating cells during early haemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukaemia. Bone Marrow Transplant 12 (1993) 267-271
5. Carella A.M., Lerma E., Corsetti M.T., et al. Autografting with Philadelphia chromosome-negative mobilised hematopoietic progenitor cells in chronic myeloid leukaemia. Blood 83 (1999) 1534-1539
6. Barnett M.J., Eaves C.J., Philips G.L., Gascoyne R.D., Hogge D.E., Horsman D.E., et al. Autografting with cultured marrow in chronic myeloid leukaemia: results of pilot study. Blood 84 (1994) 724-732
7. McGlave P.B., De Fabritis P., Deisseroth A., et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 343 (1994) 1486-1488
8. Reiffers J., Goldman J., Meloni G., Cahn J.Y., and Gratwohl A. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 14 3 (1994) 407-410
9. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J-L, Maloisel F, et al. for The French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-9.
10. Giles F.J., Shan J., Chen S., Advani S.H., Supandiman I., Aziz Z., et al. A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study. Leukemia Lymphoma 37 (2000) 367-377
11. Tothova E., Fricova M., Kakkova A., Stecova N., Guman T., Raffac S., et al. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia. Neoplasma 47 (2000) 125-128
12. Baccarani M., Rosti G., de-Vivo A., Bonifazi F., Russo D., Martinelli G., et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99 (2002) 1527-1535
13. Kuhr T., Burgstaller S., Apfelbeck U., Linkesch W., Seewann H., Fridik M., et al. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leukemia Res 27 (2003) 405-411
14. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 (1992) 1-15
15. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged anti-platelet treatment. Br Med J 296 (1988) 320-331
16. Berger U., Hochhaus A., Heimpel H., Hossfeld D.K., Hasford J., Huber C., et al. Randomized treatment intensification with high dose chemotherapy followed by autografting in chronic myelogenous leukemia: The German CML-Study IIIA. Hematol J 1 Suppl. 1 (2000) 798
17. Hoyle C., Gray R., and Goldman J. Autografting for patients with CML in chronic phase: an update. Br J Haematol 86 1 (1994) 76-81
18. Bhatia R., Verfaillie C.M., Miller J.S., and McGlave P.B. Autologous transplantation therapy for chronic myelogenous leukemia. Blood 89 (1997) 2623-2634
19. Druker B.J., Guilhot F., O'Brien S., and Larson R.A. Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia in chronic phase: the 5-year update from the IRIS study. J Clin Oncol 24 (2006) 338s
20. Drummond M.W., Marin D., Clark R.E., Byrne J.L., Holyoake T.L., and Lennard A.L. United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party. Mobilisation of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate induced complete cytogenetic remission. Br J Haematol 123 3 (2003) 479-483
21. Hui C.H., Goh K.Y., White D., Branford S., Grigg A., Seymour J.F., et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 17 (2003) 821-828
22. Kreuzer K.-A., Klühs C., Baskaynak G., Movassaghi K., Dörken B., and le Coutre P. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 24 (2004) 195-199